Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ascendis Pharma A/S (Nasdaq: ASND) will host a conference call and live webcast on April 27, 2023, at 4:30 p.m. ET to discuss its Q1 2023 financial results and provide a business update. Interested participants can access the live event via the company's website. A replay will be available for 30 days post-event. The company is leveraging its innovative TransCon platform technology to advance its biopharmaceutical portfolio, focusing on developing potentially best-in-class therapies. Ascendis operates out of multiple locations, including Denmark and the US, reflecting its global reach and commitment to improving patient outcomes.